^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    vepdegestrant (ARV-471)

    i
    Company:
    Arvinas, Pfizer
    Drug class:
    Ubiquitin pathway modulator, Estrogen receptor alpha degrader
    Related drugs:
    Apply
    TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) (TACTIVE-U Sub-Study B) (NCT05573555)
    Phase 1/2
    Pfizer
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    03/01/2023
    Primary completion :
    12/30/2026
    Completion :
    12/30/2026
    HER-2
    |
    HER-2 negative
    |
    Kisqali (ribociclib) • vepdegestrant (ARV-471)
    A Phase 1/2 Trial of ARV-471 Alone and in Combination with Palbociclib (IBRANCE®) in Patients with ER+/HER2- Locally Advanced or Metastatic Breast Cancer (VERITAC) (NCT04072952)
    Phase 1/2
    Arvinas Estrogen Receptor, Inc.
    Active, not recruiting
    Last update posted :
    02/11/2025
    Initiation :
    08/05/2019
    Primary completion :
    09/13/2024
    Completion :
    03/13/2025
    HER-2
    |
    HER-2 negative
    |
    Ibrance (palbociclib) • vepdegestrant (ARV-471)
    I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY 2) (NCT01042379)
    Phase 2
    QuantumLeap Healthcare Collaborative
    Recruiting
    Last update posted :
    10/22/2024
    Initiation :
    03/01/2010
    Primary completion :
    12/01/2030
    Completion :
    12/01/2031
    HER-2 • ER
    |
    ER positive • ER negative
    |
    Keytruda (pembrolizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel • Nerlynx (neratinib) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • Talzenna (talazoparib) • Verzenio (abemaciclib) • Zejula (niraparib) • cyclophosphamide • irinotecan • Jemperli (dostarlimab-gxly) • Tukysa (tucatinib) • letrozole • veliparib (ABT-888) • Libtayo (cemiplimab-rwlc) • MK-2206 • Datroway (datopotamab deruxtecan) • Ziihera (zanidatamab-hrii) • ganitumab (AMG 479) • amcenestrant (SAR439859) • anvatabart opadotin (JNJ-0683) • metformin • Jivadco (trastuzumab duocarmazine) • Turalio (pexidartinib) • ganetespib (ADX-1612) • vepdegestrant (ARV-471) • Cosela (trilaciclib) • Fablyn (lasofoxifene) • DAN-222 • fianlimab (REGN3767) • Oraxol (oral paclitaxel/encequidar) • ladiratuzumab vedotin (SGN-LIV1A) • nelitolimod (SD-101) • patritumab (U3-1287) • rilvegostomig (AZD2936) • trebananib (AMG 386) • Kevzara (sarilumab) • Voyager-V1
    TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A) (C4891006) (NCT05548127)
    Phase 1/2
    Pfizer
    Recruiting
    Last update posted :
    06/06/2024
    Initiation :
    02/23/2023
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    HER-2
    |
    HER-2 negative
    |
    Verzenio (abemaciclib) • vepdegestrant (ARV-471)
    A Study of ARV-471 (PF-07850327) Plus Palbociclib Versus Letrozole Plus Palbociclib in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Negative Advanced Breast Cancer (VERITAC-3) (NCT05909397)
    Phase 3
    Pfizer
    Active, not recruiting
    Last update posted :
    06/06/2024
    Initiation :
    08/09/2023
    Primary completion :
    08/28/2028
    Completion :
    07/26/2030
    HER-2 • ER
    |
    HER-2 negative
    |
    Ibrance (palbociclib) • letrozole • vepdegestrant (ARV-471)
    A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery (TACTIVE-N) (NCT05549505)
    Phase 2
    Arvinas Inc.
    Active, not recruiting
    Last update posted :
    05/07/2024
    Initiation :
    02/15/2023
    Primary completion :
    07/15/2024
    Completion :
    08/15/2024
    HER-2
    |
    HER-2 negative
    |
    anastrozole • vepdegestrant (ARV-471)
    A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer. (VERITAC-2) (NCT05654623)
    Phase 3
    Pfizer
    Recruiting
    Last update posted :
    04/25/2024
    Initiation :
    03/03/2023
    Primary completion :
    08/14/2024
    Completion :
    05/15/2028
    HER-2 • ER
    |
    HER-2 negative
    |
    fulvestrant • vepdegestrant (ARV-471)
    A Study to Learn About the Study Medicine (Called ARV-471) in People With ER+/HER2- Advanced BC in China (NCT05732428)
    Phase 1
    Pfizer
    Active, not recruiting
    Last update posted :
    04/19/2024
    Initiation :
    02/20/2023
    Primary completion :
    03/29/2024
    Completion :
    11/07/2024
    HER-2 • ER
    |
    HER-2 negative
    |
    vepdegestrant (ARV-471)
    ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer (TACTIVE-E) (NCT05501769)
    Phase 1
    Arvinas Estrogen Receptor, Inc.
    Active, not recruiting
    Last update posted :
    01/22/2024
    Initiation :
    09/08/2022
    Primary completion :
    05/30/2024
    Completion :
    11/30/2024
    HER-2
    |
    everolimus • vepdegestrant (ARV-471)
    A Study to Learn About the ARV-471 (PF-07850327) in People With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (BC) (NCT05463952)
    Phase 1
    Pfizer
    Active, not recruiting
    Last update posted :
    09/18/2023
    Initiation :
    08/16/2022
    Primary completion :
    05/04/2023
    Completion :
    03/31/2024
    HER-2 • ER
    |
    HER-2 negative
    |
    vepdegestrant (ARV-471)